Prognostic Significance of Lymphovascular Space Invasion in Early-stage Low-grade Endometrioid Endometrial Cancer: a Fifteen-year Retrospective Chinese Cohort Study

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2024 Jul 30

PMID 39080611

Authors

Bowen Sun

Xiaobo Zhang

Yangyang Dong

Xingchen Li

Xiao Yang

Lijun Zhao

Jianliu Wang

Yuan Cheng

Affiliations

Soon will be listed here.

Abstract

Objective: In 2016, the ESMO-ESGO-ESTRO consensus included LVSI (Lymph-vascular space invasion, LVSI) status as a risk stratification factor for stage I endometrioid endometrial cancer (EEC) patients and as one of the indications for adjuvant therapy. Furthermore, LVSI is included in the new FIGO staging of endometrial cancer (EC) in 2023. However, the data contribution of the Chinese population in this regard is limited. The present study aimed to further comfirm the influence of LVSI on the prognosis of early-stage low-grade EEC in a fifteen-year retrospective Chinese cohort study.

Methods: This retrospective analysis cohort included 702 EEC patients who underwent TAH/BSO surgery, total abdominal hysterectomy, bilateral salpingooophorectomy in Peking University People's Hospital from 2006 to 2020. Patients were stratified based on LVSI expression status as: LVSI negative group and LVSI positive group. Clinical outcome measures related to LVSI, assessed with a univariate and multivariate Cox proportional hazards regression model.

Results: 702 EEC patients with stage I and grade 1-2 were analyzed. 58 patients (8.3%) were LVSI-positive and 14 patients (2.0%) was relapse. Recurrence rates in LVSI-negative and LVSI-positive were 1.6% and 6.9%, respectively. 5-year disease-free survival (DFS) rate in LVSI-negative and LVSI-positive were 98.4% and 93.1%, respectively. These rates for 5-year overall (OS) survival in LVSI-negative were 98.9% while it was 94.8% in LVSI-positive. Multivariate analysis showed that LVSI is an independent risk factor for 5-year DFS (HR = 4.60, p = 0.010). LVSI has a similar result for 5-year OS(HR = 4.39, p = 0.028).

Conclusions: LVSI is an independent predictor of relapse and poor prognosis in early-stage low-grade endometrioid endometrial cancer in the Chinese cohort.

References

Li Y, Cong P, Wang P, Peng C, Liu M, Sun G . Risk factors for pelvic lymph node metastasis in endometrial cancer. Arch Gynecol Obstet. 2019; 300(4):1007-1013. DOI: 10.1007/s00404-019-05276-9. View

Dou Y, Song K, Fu Y, Shen Y, Zhang C, Yao S . Risk Factors and Prognosis of Early Recurrence in Stage I-II Endometrial Cancer: A Large-Scale, Multi-Center, and Retrospective Study. Front Med (Lausanne). 2022; 9:808037. PMC: 9046937. DOI: 10.3389/fmed.2022.808037. View

Restaino S, Tortorella L, Dinoi G, Zannoni G, Baroni A, Capasso I . Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications. Eur J Cancer. 2020; 142:29-37. DOI: 10.1016/j.ejca.2020.10.011. View

Keys H, Roberts J, Brunetto V, Zaino R, Spirtos N, Bloss J . A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(3):744-51. DOI: 10.1016/j.ygyno.2003.11.048. View

Yarandi F, Shirali E, Akhavan S, Nili F, Ramhormozian S . The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer. Eur J Med Res. 2023; 28(1):118. PMC: 10012545. DOI: 10.1186/s40001-023-01084-9. View

Buechi C, Siegenthaler F, Sahli L, Papadia A, Saner F, Mohr S . Real-World Data Assessing the Impact of Lymphovascular Space Invasion on the Diagnostic Performance of Sentinel Lymph Node Mapping in Endometrial Cancer. Cancers (Basel). 2024; 16(1). PMC: 10778553. DOI: 10.3390/cancers16010067. View

Miller H, Tran A, LyBarger K, Frieboes H . A clinical marker-based modeling framework to preoperatively predict lymph node and vascular space involvement in endometrial cancer patients. Eur J Surg Oncol. 2023; 50(1):107309. DOI: 10.1016/j.ejso.2023.107309. View

Creasman W, Odicino F, Maisonneuve P, Quinn M, Beller U, Benedet J . Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S105-43. DOI: 10.1016/S0020-7292(06)60031-3. View

Pifer P, Jaishankar S, Bhargava R, Schad M, Keller A, Musunuru H . Is Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer?. Int J Radiat Oncol Biol Phys. 2023; 117(1):148-153. PMC: 11225593. DOI: 10.1016/j.ijrobp.2023.02.053. View

10.

Dai Y, Dong Y, Cheng Y, Hou H, Wang J, Wang Z . Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: a retrospective study from a single center. J Gynecol Oncol. 2020; 31(3):e27. PMC: 7189077. DOI: 10.3802/jgo.2020.31.e27. View

11.

Lee Y, Lai Y, Kim M, Chang K, Kim H, Cheng W . Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan. J Gynecol Oncol. 2023; 35(3):e33. PMC: 11107281. DOI: 10.3802/jgo.2024.35.e33. View

12.

Mariani A, Webb M, Keeney G, Haddock M, Calori G, Podratz K . Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol. 2000; 182(6):1506-19. DOI: 10.1067/mob.2000.107335. View

13.

Bogani G, Giannini A, Vizza E, Di Donato V, Raspagliesi F . Sentinel node mapping in endometrial cancer. J Gynecol Oncol. 2023; 35(1):e29. PMC: 10792208. DOI: 10.3802/jgo.2024.35.e29. View

14.

Stalberg K, Bjurberg M, Borgfeldt C, Carlson J, Dahm-Kahler P, Floter-Radestad A . Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncol. 2019; 58(11):1628-1633. DOI: 10.1080/0284186X.2019.1643036. View

15.

Bayramoglu D, Secilmis Kerimoglu O, Bayramoglu Z, Cintesun E, Sahin G, Karabagli P . Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods. Ginekol Pol. 2022; 94(1):3-11. DOI: 10.5603/GP.a2021.0177. View

16.

Ureyen I, Karalok A, Turkmen O, Kimyon G, Akdas Y, Akyol A . Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI?. Arch Gynecol Obstet. 2019; 301(3):737-744. DOI: 10.1007/s00404-019-05418-z. View

17.

LyBarger K, Miller H, Frieboes H . CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. Sci Rep. 2022; 12(1):19783. PMC: 9671890. DOI: 10.1038/s41598-022-22026-1. View

18.

Hui C, Mendoza M, von Eyben R, Dorigo O, Litkouhi B, Renz M . Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?. Gynecol Oncol. 2023; 177:150-156. DOI: 10.1016/j.ygyno.2023.09.001. View

19.

Qin Z, Wang Y, Chen Y, Zheng A, Han L . Evaluation of prognostic significance of lymphovascular space invasion in early stage endometrial cancer: a systematic review and meta-analysis. Front Oncol. 2024; 13:1286221. PMC: 10808564. DOI: 10.3389/fonc.2023.1286221. View

20.

Navarro B, Margioula-Siarkou C, Petousis S, Floquet A, Babin G, Guyon F . Surgical restaging of patients with early‑stage endometrial cancer with lymphovascular invasion does not significantly impact their survival outcomes. Oncol Lett. 2023; 25(3):122. PMC: 9950339. DOI: 10.3892/ol.2023.13708. View